L - PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
L - PHARMA
Largest movements
- Cash -€86
down €86 (-89.7%), from €96 to €10
mainly Net result for the year (-€3,853)
- Profit (loss) carried forward -€3,853
down €3,853 (-0.7%), from -€579,700 to -€583,553
- Other debts +€3,117
up €3,117 (+76.7%), from €4,065 to €7,182
- Trade debts +€650
up €650 (+47.7%), from €1,363 to €2,013
- Gross operating margin -€2,421
down €2,421 (-187.1%), from -€1,294 to -€3,714
- Other operating charges -€88
down €88 (-42.3%), from €208 to €120
- Depreciation -€73
no longer reported in 2025 (was €73)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €96 | €10 | -€86 | -89.7% |
| Current assets | 29/58 | €96 | €10 | -€86 | -89.7% |
| Cash at bank and in hand | 54/58 | €96 | €10 | -€86 | -89.7% |
| Total equity and liabilities | 10/49 | €96 | €10 | -€86 | -89.7% |
| Equity | 10/15 | -€505,332 | -€509,185 | -€3,853 | -0.8% |
| Contributions | 10/11 | €74,368 | €74,368 | = | 0.0% |
| Capital | 10 | €74,368 | €74,368 | = | 0.0% |
| Issued capital | 100 | €74,368 | €74,368 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€579,700 | -€583,553 | -€3,853 | -0.7% |
| Amounts payable | 17/49 | €505,428 | €509,194 | +€3,767 | +0.7% |
| Amounts payable after more than one year | 17 | €500,000 | €500,000 | = | 0.0% |
| Financial debts | 170/4 | €500,000 | €500,000 | = | 0.0% |
| Amounts payable within one year | 42/48 | €5,428 | €9,194 | +€3,767 | +69.4% |
| Trade debts | 44 | €1,363 | €2,013 | +€650 | +47.7% |
| Suppliers | 440/4 | €1,363 | €2,013 | +€650 | +47.7% |
| Other amounts payable | 47/48 | €4,065 | €7,182 | +€3,117 | +76.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €73 | - | -€73 | |
| Other operating charges | 640/8 | €208 | €120 | -€88 | -42.3% |
| Gross operating margin | 9900 | -€1,294 | -€3,714 | -€2,421 | -187.1% |
| Operating profit (loss) | 9901 | -€1,575 | -€3,834 | -€2,260 | -143.5% |
| Financial income | 75/76B | - | €9 | +€9 | |
| Recurring financial income | 75 | - | €9 | +€9 | |
| Financial charges | 65/66B | €39 | €27 | -€11 | -28.9% |
| Recurring financial charges | 65 | €39 | €27 | -€11 | -28.9% |
| Profit (loss) for the period before taxes | 9903 | -€1,613 | -€3,853 | -€2,239 | -138.8% |
| Profit (loss) for the period | 9904 | -€1,613 | -€3,853 | -€2,239 | -138.8% |
| Profit (loss) for the period to be appropriated | 9905 | -€1,613 | -€3,853 | -€2,239 | -138.8% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 4 October 2026 via checked.be.